International journal of pharmaceutics: X
Cure8 research brief
Why This Matters
This study describes a new formulation of baicalein that improved drug solubility and oral absorption and showed benefit in a mouse model of ulcerative colitis—early-stage research that could inform future drug-development efforts relevant to IBD treatment options.
Who Should Pay Attention
Researchers studying drug formulation or IBD therapeutics, clinicians who follow preclinical pharmacology advances, and patients interested in emerging IBD treatment research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper reports a laboratory and animal study of baicalein formulated as a solid dispersion (BAC‑SD) using PVP and HPMC to improve solubility and oral absorption.
The authors describe characterization (SEM, PXRD, DSC, FT‑IR), in vitro permeability tests (Caco‑2 and MDCK cells), rat pharmacokinetics showing higher bioavailability, and therapeutic effects in a DSS mouse model of ulcerative colitis (reduced DAI, inflammatory cytokines, and improved colon pathology).
The work is preclinical: findings combine formulation chemistry, cell permeability assays, rodent pharmacokinetics, and a mouse colitis model rather than human data.
The report suggests BAC‑SD increases solubility, permeability, and relative oral bioavailability versus unformulated baicalein and that the formulation reduced markers of inflammation in DSS mice. If you read the paper directly, note this is an abstract-level summary of the article provided by the journal listing, not a clinical guideline.
It summarizes methods and reported preclinical outcomes but does not provide clinical safety or efficacy data in people.
Keep In Mind
Preclinical findings in cells and rodent models do not predict effects or safety in humans. The article reports formulation and animal-model results; clinical trials would be required before any change in patient care could be recommended.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternational journal of pharmaceutics: X
AuthorsWei X, Ji X, Li Z +3 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 11, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Colon-targeting pH-responsive Bletilla striata polysaccharide coacervate microdroplets for ulcerative colitis therapy via macrophage reprogramming
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...
Therapeutic Efficacy of a Novel Oral NRF2 Activator in a Murine Ulcerative Colitis Model 2256177
The study presents a new oral NRF2 activator that reduced inflammation and tissue injury in a mouse model of ulcerative colitis, suggesting a potential novel therapeutic approach.
Development of double emulsions loaded with Malus baccata (Linn.) polyphenols and their protective effect on dextran sulfate sodium-induced ulcerative colitis in mice.
Researchers are exploring plant polyphenols and new oral delivery systems that might reduce gut inflammation and modify microbiota — findings in mice suggest potential but are not directly applicable to patients yet.